Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Nasopharyngeal Carcinoma 5Nasopharyngeal Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Unresectable Non-small Cell Lung Cancer 1Squamous Non-small Cell Lung Cancer 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lung Neoplasms 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Pancreatic Cancer 1Adenoma, Islet Cell 1

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unresectable Non-small Cell Lung Cancer × Endostatins × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡